LTZ-301: First-in-Class Myeloid Engager Immunotherapy IND Cleared by FDA
LTZ Therapeutics received FDA clearance for its Investigational New Drug (IND) application for LTZ-301. LTZ-301, a first-in-class myeloid engager...
Regeneron db-oto Results Show Hearing Improvement in Children with Genetic Hearing Loss
Regeneron Pharmaceuticals announced updated positive data from its ongoing Phase 1/2 CHORD trial of DB-OTO, a gene therapy for...
EMA and EU-Medicines for All Validate Lenacapavir HIV Prevention Application
Gilead Sciences announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) and EU-Medicines for...
FDA Clears Ruxolitinib Phase 2 Study for Dermatomyositis Treatment
NovelMed Therapeutics has received FDA clearance to initiate a Phase II efficacy trial of Ruxoprubart (NM8074) for Dermatomyositis (DM),...
Synergia Medical Announces Strong Results for nao.vns First-in-Human Study
Synergia Medical’s NAO.VNS™ device, implanted in five patients in Belgium, has met its primary safety endpoint in the AURORA...
Allo-Inkt Combination Data in 2L Gastric Cancer at AACR
MiNK Therapeutics presented Phase 2 data at the AACR IO Annual Meeting showcasing the potential of its allogeneic iNKT...
Leronlimab Shows Promise in mTNBC Patient Survival
CytoDyn Inc. announced encouraging survival outcomes in a group of patients with metastatic triple-negative breast cancer (mTNBC) treated with...
Versamune® HPV Clinical Cancer Research Results
PDS Biotechnology Corporation announced positive clinical trial results for its lead immunotherapy candidate, Versamune® HPV, in the treatment of...
Calidi Starts High-Grade Glioma Trial Recruitment
Calidi Biotherapeutics has begun enrolling patients at Northwestern University/Northwestern Memorial Hospital for a clinical trial of CLD-101, an immunotherapy...
Brain Exercise Lowers Fatigue in MS Study
Researchers at New York University (NYU) found that brain exercises from the BrainHQ app, developed by Posit Science, reduced...